SPILF update on bacterial arthritis in adults and children.

{"article_title":"SPILF update on bacterial arthritis in adults and children.","author":"Stahl JP, Canou\u00ef E, Pavese P, Bleibtreu A, Dub\u00e9e V, Ferry T, Gillet Y, Lemaignen A, Lorrot M, Lourtet-Hasco\u00ebt J, Manaquin R, Meyssonnier V, Pham TT, Varon E, Lesprit P, Gauzit R","journal_title":"Infectious diseases now","issn":"2666-9919","isbn":"","publication_date":"2023-06-01","volume":"53","issue":"4","first_page":"104694","page_count":"","accession_number":"36948248","doi":"10.1016\/j.idnow.2023.104694","publisher":"Elsevier Masson","doctype":"Practice Guideline","subjects":"Staphylococcal Infections drug therapy; Arthritis, Infectious diagnosis; Arthritis, Infectious drug therapy; Humans; Adult; Child; Anti-Bacterial Agents therapeutic use; Administration, Oral; Administration, Intravenous","interest_area":["Infectious Disease & Vaccines"," Pediatric Medicine"],"abstract":"In 2020 the French Society of Rhumatology (SFR) published an update of the 1990 recommendations for management of bacterial arthritis in adults. While we (French ID Society, SPILF) totally endorse this update, we wished to provide further information about specific antibiotic treatments. The present update focuses on antibiotics with good distribution in bone and joint. It is important to monitor their dosage, which should be maximized according to PK\/PD parameters. Dosages proposed in this update are high, with the optimized mode of administration for intravenous betalactams (continuous or intermittent infusion). We give tools for the best dosage adaptation to conditions such as obesity or renal insufficiency. In case of enterobacter infection, with an antibiogram result \"susceptible for high dosage\", we recommend the requesting of specialized advice from an ID physician. More often than not, it is possible to prescribe antibiotics via the oral route as soon as blood cultures are sterile and clinical have symptoms shown improvement. Duration of antibiotic treatment is 6 weeks for Staphylococcus aureus, and 4 weeks for the other bacteria (except for Neisseria: 7 days). Copyright \u00a9 2023 Elsevier Masson SAS. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=36948248","isPdfLink":false,"isSAML":false,"an":"36948248","number_other":"","type_pub":"","issn_electronic":"2666-9919","languages":"English","language":"eng","date_entry":"Date Created: 20230322 Date Completed: 20230619 Latest Revision: 20230619","date_update":"20240105","titleSource":"Infectious diseases now [Infect Dis Now] 2023 Jun; Vol. 53 (4), pp. 104694. Date of Electronic Publication: 2023 Mar 21.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2023-06-01","description":"In 2020 the French Society of Rhumatology (SFR) published an update of the 1990 recommendations for management of bacterial arthritis in adults. While we (French ID Society, SPILF) totally endorse this update, we wished to provide further information about specific antibiotic treatments. The present update focuses on antibiotics with good distribution in bone and joint. It is important to monitor their dosage, which should be maximized according to PK\/PD parameters. Dosages proposed in this update are high, with the optimized mode of administration for intravenous betalactams (continuous or intermittent infusion). We give tools for the best dosage adaptation to conditions such as obesity or renal insufficiency. In case of enterobacter infection, with an antibiogram result "susceptible for high dosage", we recommend the requesting of specialized advice from an ID physician. More often than not, it is possible to prescribe antibiotics via the oral route as soon as blood cultures are sterile and clinical have symptoms shown improvement. Duration of antibiotic treatment is 6 weeks for Staphylococcus aureus, and 4 weeks for the other bacteria (except for Neisseria: 7 days).<br \/> (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=36948248&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Stahl JP, Canou\u00ef E, Pavese P, Bleibtreu A, Dub\u00e9e V, Ferry T, Gillet Y, Lemaignen A, Lorrot M, Lourtet-Hasco\u00ebt J, Manaquin R, Meyssonnier V, Pham TT, Varon E, Lesprit P, Gauzit R"}